The CD38+ IgD+ CD24− B cell subset was positively associated with BC risk, with the effect mediated by the acylcarnitine metabolite pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC). This evidence concerns the gene CD24 and breast cancer.